SCHEMBL13052166

SCHEMBL13052166

Cc1[nH]c(/C=C2\C(=O)Nc3ccccc32)c(C)c1C

nearest known ligand 0.80

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDR P35968 10/20 0.80
PDGFRB P09619 6/20 0.76
FGFR1 P11362 7/20 0.66
RET P07949 5/20 0.66
FLT3 P36888 5/20 0.66
ALK Q9UM73 5/20 0.66
FLT1 P17948 4/20 0.66
AURKA O14965 3/20 0.66
MAP4K2 Q12851 3/20 0.66
STK3 Q13188 3/20 0.66
AURKB Q96GD4 3/20 0.66
CSF1R P07333 3/20 0.66
FGFR3 P22607 3/20 0.66
FLT4 P35916 3/20 0.66
ZAP70 P43403 2/20 0.66
ABL1 P00519 2/20 0.66
PLK4 O00444 2/20 0.66
PDPK1 O15530 2/20 0.66
JAK2 O60674 2/20 0.66
PRKD3 O94806 2/20 0.66

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5475086 0.89 KDR (1.00) KDRPDGFRBFGFR1RETFLT3
SCHEMBL5469528 0.89 KDR (1.00) KDRPDGFRBFGFR1RETFLT3
SCHEMBL5469533 0.89 KDR (1.00) KDRPDGFRBFGFR1RETFLT3
SCHEMBL5475085 0.89 KDR (1.00) KDRPDGFRBFGFR1RETFLT3
SCHEMBL6001617 0.88 KDR (0.67) KDRPDGFRBFGFR1RETFLT3
SCHEMBL6001621 0.88 KDR (0.67) KDRPDGFRBFGFR1RETFLT3
SCHEMBL13101870 0.88 KDR (0.70) KDRPDGFRBFGFR1RETFLT3
SCHEMBL7416754 0.87 KDR (0.74) KDRPDGFRBFGFR1RETFLT3
SCHEMBL7416755 0.87 KDR (0.74) KDRPDGFRBFGFR1RETFLT3
SCHEMBL6000845 0.86 PDGFRB (1.00) KDRPDGFRBFGFR1RETFLT3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100298376-A1 USE OF NOVEL NEUROPROTECTIVE 3-SUBSTITUTED INDOLONE COMPOSITIONS BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) 2010-11-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100298376-A1 USE OF NOVEL NEUROPROTECTIVE 3-SUBSTITUTED INDOLONE COMPOSITIONS NLN, HTT, PARK7 KDR 3586/4885PDGFRB 2159/4885FGFR1 4427/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.